His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2
GH/IGF axis / recovery
Recovery, body composition, and anabolic signaling support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- GH/IGF-axis peptide
- Primary mechanism
- Growth hormone / IGF pathway modulation
- Primary market use
- GH/IGF axis / recovery
Pharmacology
- Molecular weight (Da)
- 998.06
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 6 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels.